# Biohaven Drives New Research in Graves' Disease: Phase 3 Pivotal Trial with BHV-1300 Underway and Three Scientific Posters at the 2026 American Thyroid Association Annual (ATA) Meeting

- Source: PR Newswire M&A
- Published: 2026-11-05T12:30:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/biohaven-drives-new-research-in-graves-disease-phase-3-pivotal-trial-with-bhv-1300-underway-and-three-scientific-posters-at-the-2026-american-thyroid-association-annual-ata-meeting-302930094.html
- Canonical: https://groundlevelnews.com/story/biohaven-drives-new-research-in-graves-disease-phase-3-pivotal-trial-w-d7289d/

Biohaven presents three posters at ATA, highlighting the patient experience, autoimmune biology of disease, and MoDE and TRAP platform, reflecting a research program built around a condition that remains strikingly understudied relative to its prevalence. No new therapy has been approved...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._